Sanofi mRNA vaccine candidate (hMPV/RSV)

mRNA vaccine encapsulated in lipid nanoparticle formulation targeting human metapneumovirus and respiratory syncytial virus · Sanofi Pasteur

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sanofi mRNA vaccine candidate (hMPV/RSV), covering 2025-12-11 to 2025-12-11. Get the full timeline:

Most recent: Clinical Trial Update: Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older [Phase 1, Phase 2]

See pricing